A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

The Food and Drug Administration (FDA) has updated the labeling for Kisunla ™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer ...

Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance ...

LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.

While the year started out as cautiously optimistic, stemming from the peak of biotech initial public offering (IPO) activity ...

A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug ...

The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.

Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in approving the drug.

ALIA-1758 targets pyroglutamate amyloid beta – in a similar way to Kisunla – but the use of MODEL technology means it should be able to reach higher concentrations in the brain and dissolve ...

Mitolyn is a natural weight loss supplement designed to target a hidden cause of stubborn fat—poor mitochondrial health. Based on Harvard research ...